{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:01:34Z","timestamp":1790683294063,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40744-026-00861-2","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:25:43Z","timestamp":1784903143000},"page":"1273-1285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistence Among Biologic\/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs"],"prefix":"10.1007","volume":"13","author":[{"given":"Taylor T.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanke","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"N\u2019Dri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofer","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vardhaman A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wittstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Khaychuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"861_CR1","unstructured":"Rheumatoid Arthritis. 2021; https:\/\/www.rheumatology.org\/I-Am-A\/Patient-Caregiver\/Diseases-Conditions\/Rheumatoid-Arthritis."},{"key":"861_CR2","doi-asserted-by":"crossref","unstructured":"Derksen V, Huizinga T, Van Der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Paper presented at: Seminars in Immunopathology 2017.","DOI":"10.1007\/s00281-017-0627-z"},{"issue":"5","key":"861_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar1767","volume":"7","author":"A van der Helm-van Mil","year":"2005","unstructured":"van der Helm-van Mil A, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7(5):1\u201310.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"861_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.12829","volume":"294","author":"M Volkov","year":"2020","unstructured":"Volkov M, van Schie KA, van der Woude D. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunol Rev. 2020;294(1):148\u201363.","journal-title":"Immunol Rev"},{"issue":"6","key":"861_CR5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"861_CR6","doi-asserted-by":"publisher","DOI":"10.3831\/KPI.2019.22.029","volume":"22","author":"D Kesharwani","year":"2019","unstructured":"Kesharwani D, Paliwal R, Satapathy T, Paul SD. Rheumatoid arthritis: An updated overview of latest therapy and drug delivery. J Pharmacopunct. 2019;22(4):210.","journal-title":"J Pharmacopunct"},{"key":"861_CR7","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519.","journal-title":"J Inflamm Res"},{"issue":"7","key":"861_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, et al. JAK-inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules. 2020;10(7):1002.","journal-title":"Biomolecules"},{"issue":"1","key":"861_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0697-z","volume":"17","author":"I Contreras-Y\u00e1\u00f1ez","year":"2015","unstructured":"Contreras-Y\u00e1\u00f1ez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther. 2015;17(1):1\u20139.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"861_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","volume":"54","author":"J Bluett","year":"2015","unstructured":"Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology. 2015;54(3):494\u20139.","journal-title":"Rheumatology"},{"key":"861_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S140457","volume":"11","author":"L Li","year":"2017","unstructured":"Li L, Cui Y, Yin R, et al. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Patient Prefer Adherence. 2017;11:1343.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"861_CR12","first-page":"882","volume":"27","author":"ME Peter","year":"2021","unstructured":"Peter ME, Zuckerman AD, DeClercq J, et al. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy. J Manag Care Spec Pharm. 2021;27(7):882\u201390.","journal-title":"J Manag Care Spec Pharm"},{"issue":"supp1","key":"861_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/annrheumdis-2020-eular.1255","volume":"79","author":"W Rigby","year":"2020","unstructured":"Rigby W, Buckner J, Bridges S Jr, et al. THU0160 the effect of HLA-DRB1 risk alleles on the clinical efficacy and safety of abatacept in seropositive, biologic-naive patients with early, moderate-to-severe RA treated with abatacept or adalimumab: data from the open-label switch period of the head-to-head single-blinded early AMPLE trial. Ann Rheum Dis. 2020;79(supp1):295.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"861_CR14","first-page":"192","volume":"11","author":"MM Bonafede","year":"2018","unstructured":"Bonafede MM, McMorrow D, Proudfoot C, Shinde S, Kuznik A, Chen C-I. Treatment persistence and healthcare costs among patients with rheumatoid arthritis after a change in targeted therapy. Am Health & Drug benef. 2018;11(4):192.","journal-title":"Am Health & Drug benef"},{"issue":"1","key":"861_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1917-8","volume":"21","author":"D Choquette","year":"2019","unstructured":"Choquette D, Bessette L, Alemao E, et al. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata\u00ae clinical database and registry. Arthritis Res Ther. 2019;21(1):1\u20139.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"861_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-2100-y","volume":"22","author":"G Cagnotto","year":"2020","unstructured":"Cagnotto G, Willim M, Nilsson J-\u00c5, et al. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors\u2014data from a large national quality register. Arthritis Res Ther. 2020;22(1):1\u201311.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"861_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40744-019-0149-3","volume":"6","author":"LR Harrold","year":"2019","unstructured":"Harrold LR, Litman HJ, Connolly SE, et al. Comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are anti-CCP positive in the United States Corrona Registry. Rheumatol and Ther. 2019;6(2):217\u201330.","journal-title":"Rheumatol and Ther"},{"issue":"3","key":"861_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003160","volume":"9","author":"K Ebina","year":"2023","unstructured":"Ebina K, Etani Y, Maeda Y, et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD Open. 2023;9(3):e003160.","journal-title":"RMD Open."},{"key":"861_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48537-z","volume":"13","author":"K Takami","year":"2023","unstructured":"Takami K, Tsuji S. Real-world retention rates of biologics in patients with rheumatoid arthritis. Sci Rep. 2023;13:21170.","journal-title":"Sci Rep"},{"issue":"4","key":"861_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"861_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002571","volume":"8","author":"JI Weitz","year":"2022","unstructured":"Weitz JI, Szekanecz Z, Charles-Schoeman C, et al. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 2022;8(2):e002571.","journal-title":"RMD Open"},{"issue":"1","key":"861_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119\u201329.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00861-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:28:52Z","timestamp":1790681332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00861-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00861-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Taylor T Schwartz, Kristofer Norris: employee of Avalere, a company which received funding from Bristol Myers Squibb to perform the study and provides advisory services to the life sciences industry. Hanke Zheng: Fellowship with Bristol Myers Squibb. Laetitia N\u2019Dri, Sang Hee Park, Vardhaman A Patel, Keith Wittstock, Vadim Khaychuk: employees and stockholders of Bristol Myers Squibb. Scott B Robinson, Alison R Silverstein: employees of Inovalon, a company which received funding from Bristol Myers Squibb to perform the study and provides advisory services to the life sciences industry. Jeffrey A Sparks: research funding: Arthritis Foundation, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Llura Gund Award of the Gordon and Llura Gund Foundation, National Heart, Lung, and Blood Institute (R01 HL155522), National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR080659, R01 AR077607, P30 AR070253, and P30 AR072577), R. Bruce and Joan M. Mickey Research Scholar Fund, Rheumatology Research Foundation, and Sonoma Biotherapeutics; consulting fees: AbbVie, Amgen, Anaptys, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Gilead, Inova Diagnostics, Invivyd, Johnson & Johnson\/Janssen, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi, and UCB. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health. The following authors have updated affiliations since the time of the analysis: Laetitia N\u2019Dri (Merck), Vardhaman A Patel (Genmab), Scott B Robinson (ZS), Vadim Khaychuk (Biogen), Alison R Silverstein (EntityRisk).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was a secondary data analysis of statistically de-identified data, obtaining ethics approval and patient consent was not necessary. Approval to access the Medicare data is governed by an established research-oriented data use agreement with Centers for Medicare & Medicaid Services. Approval to access the Prognos laboratory data was governed by a data use agreement with Prognos.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}